CrushSCI.com
169.6Average days
163Median days
29Fastest days
350Longest days
3732025 publications

Paper Review Records

All Paper Review Records

27 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

142 days

Toxicity, health-related quality of life and sexuality after molecular profile-based adjuvant treatment in high-intermediate risk endometrial cancer, PORTEC-4a

Authors
Anne Sophie V. M. Van den Heerik; Cathalijne C. B. Post; Marie A. D. Haverkort; Nienke Kuijsters; Stefan Kommoss; Friederike L. A. Koppe; Marlies E. Nowee; Henrike Westerveld; Maria A. A. De Jong; Filip Frühauf; Jeltsje S. Cnossen; Jan Willem M. Mens; Jannet C. Beukema; Cyrus Chargari; Charles Gillham; Dorine S. J. Tseng; Katrien Vandecasteele; Karen Verhoeven-Adema; Hans W. Nijman; Remi A. Nout; Bastiaan G. Wortman; Stephanie M. De Boer; Hein Putter; Vincent T. H. B. M Smit; Carien L. Creutzberg; Nanda HorewegShow moreShow less
Affiliations
1. Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands; 2. Department of Radiation Oncology, Radiotherapiegroep, Arnhem, The Netherlands; 3. Maastro, Maastricht, The Netherlands; 4. Department of Women’s Health, Tübingen University Hospital, Tübingen and Diak Klinikum, Department of Gynecology & Obstetrics, Schwaebisch Hall, Germany; 5. Institute Verbeeten, Tilburg, The Netherlands; 6. Department of Radiotherapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 7. Department of Radiation Oncology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands; 8. Department of Radiotherapy, Erasmus MC – Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands; 9. Radiotherapeutisch Instituut Friesland, Leeuwarden, The Netherlands; 10. Department of Gynaecology, Obstetrics and Neonatology, General University Hospital Prague, First Medical Faculty of the Charles University, Prague, Czech Republic; 11. Department of Radiotherapy, Catharina Hospital Eindhoven, Eindhoven, The Netherlands; 12. Department of Radiotherapy, University Medical Center Groningen, Groningen, The Netherlands; 13. Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France; 14. Department of Radiation Oncology, St. Luke’s Hospital, Dublin, Ireland and Cancer Trials, Dublin, Ireland; 15. Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands; 16. Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium; 17. Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands; 18. Department of Gynecology, University Medical Center Groningen, Groningen, The Netherlands; 19. Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands; 20. Department of Pathology, Leiden University Medical Center, Leiden, The NetherlandsShow moreShow less
Source PDF DOI Publisher page
184 days

Long-term fatigue dimensions in the Multidimensional Fatigue Inventory (MFI) up to five years after radiotherapy and their trajectories in men diagnosed with non-metastatic prostate cancer in the international REQUITE study

Authors
Philipp Heumann; Juan C. Rosas; Miguel E. Aguado-Barrera; David Azria; Axel Benner; Erik Briers; Renée Bultijnck; Ananya Choudhury; Antonio Gómez-Caamaño; Rudolf Kaaks; Maarten Lambrecht; Tiziana Rancati; Barry S. Rosenstein; Dirk De Ruysscher; Martina E. Schmidt; Susanne Singer; Elena Sperk; Hilary Stobart; Ana Vega; Liv Veldeman; Tim Ward; Adam Webb; Catharine M. West; Jenny Chang-Claude; Christopher J. Talbot; Tim Rattay; Petra SeiboldShow moreShow less
Affiliations
1. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 2. Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany; 3. Fundación Pública Galega de Medicina Xenómica (FPGMX), Servicio Galego de Saúde, Santiago de Compostela, Spain; 4. Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain; 5. ICM Institut du Cancer Montpellier, Montpellier, France; 6. Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany; 7. Ghent University Hospital, Ghent, Belgium; 8. Department of Human Structure and Repair, Ghent University, Ghent, Belgium; 9. University of Manchester, Christie Hospital NHS Foundation Trust, Manchester, UK; 10. Department of Radiation Oncology, Hospital Clínico Universitario de Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, Spain; 11. UZ Leuven, Leuven, Belgium; 12. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 13. Icahn School of Medicine at Mount Sinai, New York, USA; 14. MAASTRO Clinic, Maastricht, Netherlands; 15. Division of Physical Activity, Cancer Prevention and Survivorship, German Cancer Research Center (DKFZ), Heidelberg, Germany; 16. Comprehensive Cancer Center Mecklenburg Vorpommern, University Medical Center Rostock, Rostock, Germany; 17. Mannheim Cancer Center, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; 18. Biomedical Network on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Santiago de Compostela, Spain; 19. University of Leicester, Leicester, UK; 20. The University of Manchester, Manchester, UK; 21. Division of Personalized Early Detection of Prostate Cancer, German Cancer Research Center (DKFZ), Heidelberg, GermanyShow moreShow less
Source PDF DOI Publisher page
199 days

SKP2-mediated CDK4 selective degradation contributes to SCP-7e-induced cell death of non-small cell lung cancer

Authors
Qiulin Yan; Hui Ren; Haiying Xu; Xuehan Ma; Yuanqing Li; Qiurong Liu; Yi Yang; Qingbo Liu; Guo-Dong Yao; Shao-Jiang SongShow moreShow less
Affiliations
1. Key Laboratory of Computational Chemistry-Based Natural Antitumor Drug Research & Development, Liaoning Province; Engineering Research Center of Natural Medicine Active Molecule Research & Development, Liaoning Province; Key Laboratory of Natural Bioactive Compounds Discovery & Modification, Shenyang; School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China; 2. Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China; 3. Liaoning University of Traditional Chinese Medicine, Shenyang, ChinaShow moreShow less
Source PDF DOI Publisher page
319 days

Which is more effective at improving uptake of bowel cancer screening: text message reminders or patient navigation? Results from a three-arm RCT

Authors
Benzeer Siddique; Thomas Duffy; Natalie Gil; Andrew Prentice; Sarah Marshall; Natasha Djedovic; Abhinav Sundriyal; Michael Lewis; Josephine Ruwende; Ghalia Kayal; Aradhna Kaushal; Yasemin Hirst; Stephen Duffy; Christian von Wagner; Robert S. KerrisonShow moreShow less
Affiliations
1. Department of Behavioural Science and Health, University College London, London, UK; 2. St Mark’s Bowel Cancer Screening Centre, Harrow, UK; 3. Centre for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University of London, London, UK; 4. School of Health Sciences, University of Surrey, Surrey, UK; 5. St Mark’s Hospital, Harrow, UK; 6. University of Birmingham, Birmingham, UK; 7. NHS England (London), London, UK; 8. Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia; 9. Applied Health Research Hub, University of Lancashire, Lancashire, Preston, UK; 10. Centre for Cancer Screening, Prevention and Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, UKShow moreShow less
Source PDF DOI Publisher page
211 days

Long-term fatigue based on the EORTC QLQ-C30 up to five years after radiotherapy and its trajectories in men diagnosed with non-metastatic prostate cancer in the international REQUITE study

Authors
Philipp Heumann; Juan C. Rosas; Miguel E. Aguado-Barrera; David Azria; Axel Benner; Erik Briers; Renée Bultijnck; Ananya Choudhury; Antonio Gómez-Caamaño; Rudolf Kaaks; Maarten Lambrecht; Tiziana Rancati; Barry S. Rosenstein; Dirk De Ruysscher; Martina E. Schmidt; Susanne Singer; Elena Sperk; Hilary Stobart; Ana Vega; Liv Veldeman; Tim Ward; Adam Webb; Catharine M. West; Jenny Chang-Claude; Christopher J. Talbot; Tim Rattay; Petra SeiboldShow moreShow less
Affiliations
1. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 2. Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany; 3. Fundación Pública Galega de Medicina Xenómica (FPGMX), Servicio Galego de Saúde, Santiago de Compostela, Spain; 4. Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago de Compostela, Spain; 5. ICM Institut du Cancer Montpellier, Montpellier, France; 6. Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany; 7. Ghent University Hospital, Ghent, Belgium; 8. Department of Human Structure and Repair, Ghent University, Ghent, Belgium; 9. University of Manchester, Christie Hospital NHS Foundation Trust, Manchester, United Kingdom; 10. Department of Radiation Oncology, Hospital Clínico Universitario de Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, Spain; 11. UZ Leuven, Leuven, Belgium; 12. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 13. Icahn School of Medicine at Mount Sinai, New York, USA; 14. MAASTRO Clinic, Maastricht, Netherlands; 15. Division of Physical Activity, Cancer Prevention and Survivorship, German Cancer Research Center (DKFZ), Heidelberg, Germany; 16. Comprehensive Cancer Center Mecklenburg Vorpommern, University Medical Center Rostock, Rostock, Germany; 17. Mannheim Cancer Center, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; 18. Biomedical Network on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Santiago de Compostela, Spain; 19. University of Leicester, Leicester, United Kingdom; 20. The University of Manchester, Manchester, United Kingdom; 21. Division of Personalized Early Detection of Prostate Cancer, German Cancer Research Center (DKFZ), Heidelberg, GermanyShow moreShow less
Source PDF DOI Publisher page
50 days

Efflux transporter biomarkers and treatment sequencing in parp inhibitor resistance

Authors
Yuquan Yuan; Chengzhi ZhaoShow moreShow less
Affiliations
1. Department of Obstetrics and Gynecology, Chongqing Health Center for Women and Children, Chongqing, China; 2. Department of Obstetrics and Gynecology, Women and Children’s Hospital of Chongqing Medical University, Chongqing, China; 3. Chongqing Key Laboratory of Human Embryo Engineering and Precision Medicine, Chongqing, ChinaShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does BRITISH JOURNAL OF CANCER take to review a manuscript?

As of 2026-11-18, CrushSCI has 27 complete review records for BRITISH JOURNAL OF CANCER. The fastest paper went from submission to acceptance in 29 days (Oligometastatic neuroendocrine tumours: imprecision is not equivalence, received 2026-07-21, accepted 2026-08-19); the slowest took 350 days. The average is 169.6 days and the median is 163 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.